Curium and Lantheus Prevail in Patent Dispute Over Lutetium-177 Dotatate Products

Curium and Lantheus won a patent dispute concerning lutetium-177 dotatate products, used for neuroendocrine tumor imaging and therapy. The ruling could impact availability and competition in the radiopharmaceutical market.

• Curium and Lantheus successfully defended patents related to lutetium-177 dotatate.
• The dispute involved competing products in the neuroendocrine tumor theranostics space.
• The court's decision may influence future market dynamics for these agents.

RadPigeon summaries are original and for information only. They are not clinical advice.